|1.||Kanno, Takeshi: 7 articles (03/2015 - 01/2012)|
|2.||Nishizaki, Tomoyuki: 7 articles (03/2015 - 01/2012)|
|3.||Tsuchiya, Ayako: 4 articles (03/2015 - 01/2014)|
|4.||Ishii, Kenichiro: 4 articles (01/2015 - 01/2008)|
|5.||Sugimura, Yoshiki: 4 articles (01/2015 - 01/2008)|
|6.||Gotoh, Akinobu: 4 articles (07/2014 - 01/2012)|
|7.||Nakano, Takashi: 4 articles (07/2014 - 01/2013)|
|8.||Tsukamoto, Taiji: 4 articles (05/2013 - 11/2005)|
|9.||Masumori, Naoya: 4 articles (01/2011 - 11/2005)|
|10.||Kaku, Yoshiko: 3 articles (03/2015 - 07/2014)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/01/2002 - "Naftopidil tablet was safe and effective in treating benign prostatic hyperplasia."
09/01/2011 - "The present study investigated the early efficacy of naftopidil against lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). "
07/01/2004 - "The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score (IPSS) and urodynamic parameters in the treatment of benign prostatic hyperplasia (BPH). "
05/01/2013 - "Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy."
05/01/2013 - "To examine the efficacy of dose increase therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to 50 mg/day of naftopidil. "
05/01/2013 - "Among patients with nocturia improved by naftopidil, IIEF5 total score was significantly changed in the group with IPSS nocturia score ≤1 as compared to the group with IPSS nocturia score ≥2 per night (P = 0.038). "
01/01/2011 - "Men with high slow stream score and unsatisfactory improvement in nocturia may benefit from dose escalation of naftopidil."
01/01/2007 - "Improvement of nocturia and incomplete emptying by naftopidil contributed to improvement in QOL, odds ratio between the good response group and poor response group were 3.6 and 2.3, respectively. "
03/01/2015 - "Evening dosing of naftopidil seems to be more effective in treating nocturia in male patients with lower urinary tract symptoms."
04/01/2010 - "In conclusion, naftopidil appears to be an effective agent not only for nocturia and other urinary storage symptoms, but also for improving the quality of sleep."
|3.||Overactive Urinary Bladder (Overactive Bladder)
01/01/2011 - "[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]."
01/01/2006 - "Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia."
01/01/2011 - "A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. "
10/01/2008 - "To assess the effectiveness and safety of the alphala/d blocker naftopidil in the treatment of benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms. "
10/01/2008 - "[Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms]."
09/01/2013 - "In vivo tumorigenic studies showed a significant reduction of ACHN tumor weight, Ki-67 index, and microvessel density (MVD) in naftopidil-treated mice. "
01/01/2011 - "These findings demonstrated that naftopidil strongly suppressed cell proliferation of stromal cells, resulting in decreased tumorigenic soluble factor, suggesting that naftopidil might be effective in preventing stromal support of tumor cells."
01/01/2011 - "Tumorigenic studies in vivo showed significant reductions in tumor growth when E9 cells (an androgen low-sensitive LNCaP subline) grafted with PrSC were treated with naftopidil. "
01/01/2015 - "Naftopidil inhibits cell cycle progression not only in cancer cells, but also in fibroblasts and vascular endothelial cells. "
01/01/2014 - "Naftopidil drastically suppressed tumor growth in mice inoculated with these cells. "
09/01/2011 - "To evaluate the lower urinary tract symptoms predicting the efficacy of the α1-adrenoreceptor (AR) antagonist naftopidil in patients with benign prostate hyperplasia. "
09/01/2011 - "Symptoms Predictive for Efficacy of Naftopidil in Patients with Benign Prostate Hyperplasia."
04/01/2011 - "Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia."
03/01/2015 - "Naftopidil is clinically for treatment of benign prostate hyperplasia, and emerging evidence has pointed to its anticancer effect. "
04/01/2014 - "Naftopidil for the treatment of benign prostate hyperplasia: a systematic review."
|7.||Adrenergic Receptors (Adrenergic Receptor)
|1.||Phytotherapy (Herbal Therapy)